A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates

Jian Sha, Michelle L. Kirtley, Curtis Klages, Tatiana E. Erova, Maxim Telepnev, Duraisamy Ponnusamy, Eric C. Fitts, Wallace B. Baze, Satheesh K. Sivasubramani, William Lawrence, Igor Patrikeev, Jennifer E. Peel, Jourdan A. Andersson, Elena V. Kozlova, Bethany L. Tiner, Johnny Peterson, David Mcwilliams, Snehal Patel, Eric Rothe, Vladimir MotinAshok Chopra

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Currently, no plague vaccine exists in the United States for human use. The capsular antigen (Caf1 or F1) and two type 3 secretion system (T3SS) components, the low-calcium-response V antigen (LcrV) and the needle protein YscF, represent protective antigens of Yersinia pestis. We used a replication-defective human type 5 adenovirus (Ad5) vector and constructed recombinant monovalent and trivalent vaccines (rAd5-LcrV and rAd5-YFV) that expressed either the codon-optimized lcrV or the fusion gene designated YFV (consisting of ycsF, caf1, and lcrV). Immunization of mice with the trivalent rAd5-YFV vaccine by either the intramuscular (i.m.) or the intranasal (i.n.) route provided protection superior to that with the monovalent rAd5-LcrV vaccine against bubonic and pneumonic plague when animals were challenged with Y. pestis CO92. Preexisting adenoviral immunity did not diminish the protective response, and the protection was always higher when mice were administered one i.n. dose of the trivalent vaccine (priming) followed by a single i.m. booster dose of the purified YFV antigen. Immunization of cynomolgus macaques with the trivalent rAd5-YFV vaccine by the prime-boost strategy provided 100% protection against a stringent aerosol challenge dose of CO92 to animals that had preexisting adenoviral immunity. The vaccinated and challenged macaques had no signs of disease, and the invading pathogen rapidly cleared with no histopathological lesions. This is the first report showing the efficacy of an adenovirus-vectored trivalent vaccine against pneumonic plague in mouse and nonhuman primate (NHP) models.

Original languageEnglish (US)
Pages (from-to)586-600
Number of pages15
JournalClinical and Vaccine Immunology
Volume23
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Human Adenoviruses
Plague
Primates
Vaccines
Antigens
Immunization
Yersinia pestis
Macaca
Calcium
Immunity
Plague Vaccine
Animals
Gene Fusion
Pathogens
Aerosols
Adenoviridae
Codon
Needles
Fusion reactions
Genes

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates. / Sha, Jian; Kirtley, Michelle L.; Klages, Curtis; Erova, Tatiana E.; Telepnev, Maxim; Ponnusamy, Duraisamy; Fitts, Eric C.; Baze, Wallace B.; Sivasubramani, Satheesh K.; Lawrence, William; Patrikeev, Igor; Peel, Jennifer E.; Andersson, Jourdan A.; Kozlova, Elena V.; Tiner, Bethany L.; Peterson, Johnny; Mcwilliams, David; Patel, Snehal; Rothe, Eric; Motin, Vladimir; Chopra, Ashok.

In: Clinical and Vaccine Immunology, Vol. 23, No. 7, 01.07.2016, p. 586-600.

Research output: Contribution to journalArticle

Sha, J, Kirtley, ML, Klages, C, Erova, TE, Telepnev, M, Ponnusamy, D, Fitts, EC, Baze, WB, Sivasubramani, SK, Lawrence, W, Patrikeev, I, Peel, JE, Andersson, JA, Kozlova, EV, Tiner, BL, Peterson, J, Mcwilliams, D, Patel, S, Rothe, E, Motin, V & Chopra, A 2016, 'A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates', Clinical and Vaccine Immunology, vol. 23, no. 7, pp. 586-600. https://doi.org/10.1128/CVI.00150-16
Sha, Jian ; Kirtley, Michelle L. ; Klages, Curtis ; Erova, Tatiana E. ; Telepnev, Maxim ; Ponnusamy, Duraisamy ; Fitts, Eric C. ; Baze, Wallace B. ; Sivasubramani, Satheesh K. ; Lawrence, William ; Patrikeev, Igor ; Peel, Jennifer E. ; Andersson, Jourdan A. ; Kozlova, Elena V. ; Tiner, Bethany L. ; Peterson, Johnny ; Mcwilliams, David ; Patel, Snehal ; Rothe, Eric ; Motin, Vladimir ; Chopra, Ashok. / A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates. In: Clinical and Vaccine Immunology. 2016 ; Vol. 23, No. 7. pp. 586-600.
@article{3cedfcddb9074375b1c6feb21a44374b,
title = "A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates",
abstract = "Currently, no plague vaccine exists in the United States for human use. The capsular antigen (Caf1 or F1) and two type 3 secretion system (T3SS) components, the low-calcium-response V antigen (LcrV) and the needle protein YscF, represent protective antigens of Yersinia pestis. We used a replication-defective human type 5 adenovirus (Ad5) vector and constructed recombinant monovalent and trivalent vaccines (rAd5-LcrV and rAd5-YFV) that expressed either the codon-optimized lcrV or the fusion gene designated YFV (consisting of ycsF, caf1, and lcrV). Immunization of mice with the trivalent rAd5-YFV vaccine by either the intramuscular (i.m.) or the intranasal (i.n.) route provided protection superior to that with the monovalent rAd5-LcrV vaccine against bubonic and pneumonic plague when animals were challenged with Y. pestis CO92. Preexisting adenoviral immunity did not diminish the protective response, and the protection was always higher when mice were administered one i.n. dose of the trivalent vaccine (priming) followed by a single i.m. booster dose of the purified YFV antigen. Immunization of cynomolgus macaques with the trivalent rAd5-YFV vaccine by the prime-boost strategy provided 100{\%} protection against a stringent aerosol challenge dose of CO92 to animals that had preexisting adenoviral immunity. The vaccinated and challenged macaques had no signs of disease, and the invading pathogen rapidly cleared with no histopathological lesions. This is the first report showing the efficacy of an adenovirus-vectored trivalent vaccine against pneumonic plague in mouse and nonhuman primate (NHP) models.",
author = "Jian Sha and Kirtley, {Michelle L.} and Curtis Klages and Erova, {Tatiana E.} and Maxim Telepnev and Duraisamy Ponnusamy and Fitts, {Eric C.} and Baze, {Wallace B.} and Sivasubramani, {Satheesh K.} and William Lawrence and Igor Patrikeev and Peel, {Jennifer E.} and Andersson, {Jourdan A.} and Kozlova, {Elena V.} and Tiner, {Bethany L.} and Johnny Peterson and David Mcwilliams and Snehal Patel and Eric Rothe and Vladimir Motin and Ashok Chopra",
year = "2016",
month = "7",
day = "1",
doi = "10.1128/CVI.00150-16",
language = "English (US)",
volume = "23",
pages = "586--600",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - A Replication-Defective human type 5 adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates

AU - Sha, Jian

AU - Kirtley, Michelle L.

AU - Klages, Curtis

AU - Erova, Tatiana E.

AU - Telepnev, Maxim

AU - Ponnusamy, Duraisamy

AU - Fitts, Eric C.

AU - Baze, Wallace B.

AU - Sivasubramani, Satheesh K.

AU - Lawrence, William

AU - Patrikeev, Igor

AU - Peel, Jennifer E.

AU - Andersson, Jourdan A.

AU - Kozlova, Elena V.

AU - Tiner, Bethany L.

AU - Peterson, Johnny

AU - Mcwilliams, David

AU - Patel, Snehal

AU - Rothe, Eric

AU - Motin, Vladimir

AU - Chopra, Ashok

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Currently, no plague vaccine exists in the United States for human use. The capsular antigen (Caf1 or F1) and two type 3 secretion system (T3SS) components, the low-calcium-response V antigen (LcrV) and the needle protein YscF, represent protective antigens of Yersinia pestis. We used a replication-defective human type 5 adenovirus (Ad5) vector and constructed recombinant monovalent and trivalent vaccines (rAd5-LcrV and rAd5-YFV) that expressed either the codon-optimized lcrV or the fusion gene designated YFV (consisting of ycsF, caf1, and lcrV). Immunization of mice with the trivalent rAd5-YFV vaccine by either the intramuscular (i.m.) or the intranasal (i.n.) route provided protection superior to that with the monovalent rAd5-LcrV vaccine against bubonic and pneumonic plague when animals were challenged with Y. pestis CO92. Preexisting adenoviral immunity did not diminish the protective response, and the protection was always higher when mice were administered one i.n. dose of the trivalent vaccine (priming) followed by a single i.m. booster dose of the purified YFV antigen. Immunization of cynomolgus macaques with the trivalent rAd5-YFV vaccine by the prime-boost strategy provided 100% protection against a stringent aerosol challenge dose of CO92 to animals that had preexisting adenoviral immunity. The vaccinated and challenged macaques had no signs of disease, and the invading pathogen rapidly cleared with no histopathological lesions. This is the first report showing the efficacy of an adenovirus-vectored trivalent vaccine against pneumonic plague in mouse and nonhuman primate (NHP) models.

AB - Currently, no plague vaccine exists in the United States for human use. The capsular antigen (Caf1 or F1) and two type 3 secretion system (T3SS) components, the low-calcium-response V antigen (LcrV) and the needle protein YscF, represent protective antigens of Yersinia pestis. We used a replication-defective human type 5 adenovirus (Ad5) vector and constructed recombinant monovalent and trivalent vaccines (rAd5-LcrV and rAd5-YFV) that expressed either the codon-optimized lcrV or the fusion gene designated YFV (consisting of ycsF, caf1, and lcrV). Immunization of mice with the trivalent rAd5-YFV vaccine by either the intramuscular (i.m.) or the intranasal (i.n.) route provided protection superior to that with the monovalent rAd5-LcrV vaccine against bubonic and pneumonic plague when animals were challenged with Y. pestis CO92. Preexisting adenoviral immunity did not diminish the protective response, and the protection was always higher when mice were administered one i.n. dose of the trivalent vaccine (priming) followed by a single i.m. booster dose of the purified YFV antigen. Immunization of cynomolgus macaques with the trivalent rAd5-YFV vaccine by the prime-boost strategy provided 100% protection against a stringent aerosol challenge dose of CO92 to animals that had preexisting adenoviral immunity. The vaccinated and challenged macaques had no signs of disease, and the invading pathogen rapidly cleared with no histopathological lesions. This is the first report showing the efficacy of an adenovirus-vectored trivalent vaccine against pneumonic plague in mouse and nonhuman primate (NHP) models.

UR - http://www.scopus.com/inward/record.url?scp=84977624782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977624782&partnerID=8YFLogxK

U2 - 10.1128/CVI.00150-16

DO - 10.1128/CVI.00150-16

M3 - Article

C2 - 27170642

AN - SCOPUS:84977624782

VL - 23

SP - 586

EP - 600

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 7

ER -